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radiotherapy in patients receiving tyrosine kinase
inhibitor for advanced renal cell carcinoma
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and Tadashi Matsuda*Abstract
We report two cases of gastrointestinal perforation (GIP) after radiotherapy in patients receiving tyrosine kinase
inhibitor (TKI) for advanced renal cell carcinoma (RCC). Case 1 was a 61-year-old woman with lung metastases after
a radical nephrectomy for a right RCC (cT3aN0M0) treated with interferon-alpha (OIF, 5 MIU, three times per week).
She developed lytic metastases of the left femur and the left acetabulum. She was treated with palliative
radiotherapy to the metastatic portion (3 Gy × 10 fractions), and 400 mg sorafenib twice per day plus continuing
interferon alpha. She experienced sudden left lower abdominal pain after four weeks of treatment, and was
diagnosed with a perforation of the sigmoid colon with fecal peritonitis. Case 2 was a 48-year-old man with lung,
lymph node, and bone metastases after a radical nephrectomy for a right RCC (cT2N0M0), and was treated with
400 mg sorafenib twice per day. He developed lytic bone metastases of the lumbar vertebrae, which was treated
with palliative radiotherapy to L2-4 (3 Gy × 10 fractions). He experienced sudden abdominal pain after two months
of radiation treatment, and was diagnosed with a perforation of the sigmoid colon with fecal peritonitis. These
cases underwent radiotherapy, and therefore this may be related to the radiosensitivity of TKI.
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Recent advances in the understanding of the molecular
biology of advanced and metastatic renal cell carcinomas
(RCCs) have led to the development of several systemic
therapeutic agents that target vascular endothelial
growth factor (VEGF), the mammalian target of rapamy-
cin (mTOR) pathways, and these drugs have shown im-
pressive antitumor efficacy. In particular, the tyrosine
kinase inhibitor (TKI) sorafenib, which mainly blocks
VEGF pathways, is becoming one of the treatment
options for cytokine-refractory RCCs, and a first-line
therapy for selected RCC patients. And sunitinib is the
first-line therapy in advanced metastatic RCCs [1-3]. It
is expected that these TKIs could dramatically improve
the progression-free survival and overall survival of
advanced RCC patients. On the other hand, some ad-
verse effects (AE) that did not occur with cytokine* Correspondence: matsudat@hirakata.kmu.ac.jp
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reproduction in any medium, provided the ortherapy may occur when using TKIs, and may develop
into serious and fatal conditions in some cases.
Here, we report two cases of gastrointestinal perfor-
ation (GIP) after radiotherapy in patients receiving TKI
for advanced RCC.Case presentation
Patient 1
A 61-year-old woman received a radical nephrectomy
for a right RCC (cT3aN0M0) in April 2009. The patho-
logical findings confirmed a RCC, clear cell carcinoma,
pT2, G2. She developed multiple lung metastases in
January 2010. She was classified into the poor risk cat-
egory of the Memorial Sloan-Kettering Cancer Center
risk classification (MSKCC-risk), and was treated with
interferon alpha (Sumiferon, 6 MIU, three times per
week). However, the lung metastases gradually increased,
and she presented with dysbasia and left lower limb
pain. On examination, she had new metastatic lesions of
the left femur and left acetabulum, which were treatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 The arrows point at the ulcer and the perforated
portion in which a necrotic exudate was observed on the face
of the membrane serosa.
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(Figure 1). She was started on sorafenib, 400 mg twice
per day, plus continuing interferon alpha seven days
after beginning radiotherapy. After four weeks of treat-
ment, she suffered from sudden left lower abdominal
pain and abdominal guarding, and on that day, an exam-
ination revealed signs of peritonitis. She received an
emergent laparotomy. A perforation of the sigmoid
colon was observed during the operation, and a sigmoi-
dectomy and colostomy were performed. Around the
perforation in the sigmoid colon, two ulcers were
observed, and the perforation was solitary. No tumors or
diverticulitis were observed. A pathological exam
revealed that there was a remarkable, full-thickness inva-
sion of eosinophilic leukocytes around the ulcer, and also
invasion by neutrophilic leukocytes. There was a nec-
rotic exudate on the membrane serosa of the perfor-
ation, and narrow blood vessels with some thrombus
formation and organization in the vascular lumen
around the circumference of the perforation were
observed (Figures 2 and 3). However, there were no spe-
cific findings except for this serositis and narrowed
blood vessels. After the operation, she did not recover,
and died on postoperative day 29 due to severe sepsis,
and multiple organ dysfunction.
Patient 2
A 48-year-old man received a radical nephrectomy for a
right RCC (cT2N0M0) in February 2005. The patho-
logical findings confirmed a RCC, clear cell carcinoma,
pT2, G1. He developed some new lung metastases in
March 2006 (MSKCC-risk: intermediate). Although he
was started on interferon alpha (Sumiferon, 6 MIU,
three times per week), the lung metastases gradually
increased. Furthermore, lesions appeared in the right
iliac bone, thoracic vertebrae (Th3) and mediastinal
lymph nodes. He was started on sorafenib 400 mg twiceFigure 1 Computed tomography revealed the irradiated area;
the white area received 100%, and the dotted-area received
60% of the irradiation.per day in July 2008, and was treated with palliative
radiotherapy to the right iliac bone and Th3 (3 Gy x 10
fractions). In August 2009, he developed three new brain
metastatic lesions 15 mm in diameter, which were trea-
ted by cyberknife. However, we continued the sorafenib
at his request. He then developed left lower paralysis
and weakness in October 2009. Furthermore, an MRI of
the lumbar spine showed lytic bone metastases in L2-4,
which were treated with palliative radiotherapy (3 Gy x
10 fractions). Two months after radiotherapy, he pre-
sented with sudden abdominal pain, distention, and
guarding. On that day, an examination revealed signs of
peritonitis. He received an emergent laparotomy. A per-
foration of the sigmoid colon was observed during the
operation. A sigmoidectomy and colostomy were per-
formed. The perforation was solitary around theFigure 3 An Elastica van Gieson stain revealed that there were
narrowed blood vessels with some thrombus formation and
organization in the vascular lumen.
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ticulitis were observed on the circumference of the
colon. We regret that we did not submit a tissue sample
of the perforation in the sigmoid colon for pathological
exam. After the operation, he recovered and was dis-
charged from hospital. Unfortunately, he died three
months later due to cancer progression.
Discussion
The gastrointestinal complications of patients receiving
tyrosine kinase inhibitor consist of nausea, vomiting (40
to 53%) and diarrhea (43 to 53%), all of which are rela-
tively common, as well as gastrointestinal bleeding
(2.4%) and gastrointestinal perforation (0 to 0.2%), which
are relatively rare. However, these complications do pose
a material risk because in some cases, they may be quite
serious or even fatal [1,2,4].
The incidence rate of GIP during TKI therapy is gen-
erally rare. In a pivotal study on sorafenib for the treat-
ment of advanced RCCs, 451 patients with RCCs
received sorafenib with no reports of GIP [1], but two
(0.2%) instances of GIP occurred in 544 patients with
advanced RCC, and in 257 patients with gastrointestinal
stromal tumors receiving sunitinib [2,4]. There was a
0.7% incidence of GIPs during treatment for unresect-
able/metastatic renal cell carcinomas according to the
third interim analysis report of the postmarketing Sur-
veillance Review of Sorafenib in Japan. However the
details have not been reported [5]. One (0.3%) case of
GIP was reported in the randomized phase Pazopanib
trial [6] and another (0.2%) GIP case was also reported
in the phase III Bevacizumab trial [7] for locally
advanced or metastatic RCC. However, in the phase III
Axitinib trial [8] for advanced RCC, GIP was not
reported. In the phase II Axitinib trial [9] for metastatic
melanoma, one (3.1%) case of GIP was reported. How-
ever, in the use of mTOR inhibitors such as Everolimus,
and Temsirolimus for advanced RCC, GIPs were not
reported. [10,11]. Recently, one (3.8%) case of GIP was
reported in the phase 1 evaluation of telatinib, a VEGF
receptor tyrosine kinase inhibitor, in combination with
bevacizumab in subjects with advanced solid tumors
[12]. On the other hand, some recent case reports of
GIP with sunitinib or sorafenib for RCCs have been pub-
lished [13-15]; these studies are in Table 1. Except for
one patient that was diagnosed with a metastatic cancer
at the perforation site, the remaining six patients did not
have malignant findings, which may mean that colonic
tumor involvement and cancer metastases are not the
cause of the GIPs during TKI for RCC in many cases.
The radiotherapy itself does not generally have many
adverse effects. Eifel et al. reported that the incidence of
sigmoid perforation caused by high-dose radiotherapy
for cervical cancer was 0.6% at 20 years, with mostperforations occurring less than 30 months (3 to
98 months) after treatment, but the fatality rate was 41%
[16]. The tolerance dose of radiation for the normal in-
testine is 50 to 60 Gy [17,18]. In the present study, our
cases with GIP were irradiated as palliative therapy
(3 Gy x 10 fractions) against bone metastases, and did
not reach the tolerance dose. Patient 1 started sorafenib
at seven days after beginning radiotherapy, and the
bowel perforation occurred after five weeks of radiother-
apy. Patient 2 received palliative radiotherapy to L2-4 at
fifteen months after beginning sorafenib, and the bowel
perforation occurred after two months of radiotherapy.
Thus, the GIPs in our cases occurred one to two months
after the cessation of radiotherapy. We suspect that our
cases may be affected by the TKIs, because our GIPs oc-
curred earlier after the cessation of radiotherapy, and in
spite of the low dose of radiation, which does not reach
the tolerance dose for the intestine. Recently, several
preclinical studies showed that some anti-angiogenic
compounds, including TKI, may have a radiosensitizing
effect by inhibiting the VEGF pathway in normal and
cancer cells [19,20]. Normal cells, including endothelial
cells, would also increase their radiosensitivity according
to the action of the anti-angiogenic therapy, and seem to
be more susceptible to damage from radiotherapy, al-
though the mechanism is unclear [21]. We hypothesized
the cause of the GIPs in our cases might be related to
the radiosensitive nature of TKIs. However, it is still un-
proven whether TKIs truly have potential radiosensitive
activity.
The pathological findings around the perforation may
be important. Peters et al. reported that there were some
blood vessels with thrombus formation on the perfor-
ation spot [14]. In our cases, there was also serositis of
the perforation and narrowed blood vessels with some
thrombus formation and organization in their vascular
lumen around the circumference of the perforation.
However, it is unclear whether these pathological find-
ings are specific for GIP induced by TKI.
Conclusion
Here, we experienced two cases of GIP after radiother-
apy in patients receiving TKI for advanced RCCs. Al-
though GIPs during TKI therapy for RCC are rare, a
serious or fatal outcome may be expected. In particular,
when radiotherapy is performed with TKI, the radiosen-
sitizing effect of the anti-angiogenic therapy may in-
crease the risk of GIP. To clarify the risk of GIP, the
accumulation of more data on when radiotherapy is per-
formed with TKI therapy is required.
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